Title

Physiological (TCR-like) regulated lentiviral vectors for the generation of improved CAR-T cells

María Tristán-Manzano^{1*}, Noelia Maldonado-Pérez^{1*}, Pedro Justicia-Lirio^{1,2}, Pilar Muñoz¹, Marina Cortijo-Gutiérrez¹, Kristina Pavlovic^{1,3}, Rosario Jiménez-Moreno³, Sonia Nogueras³, MDolores Carmona³, Sabina Sánchez-Hernández¹, Araceli Aguilar-González^{1,4}, María Castilla⁵, Manel Juan⁵, Concepción Marañón¹, Karim Benabdellah¹, Concha Herrera³ and Francisco Martin^{1#}.

¹Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Avda. de la Ilustración 114, 18016 Granada, Spain.

²LentiStem Biotech, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), PTS, Avda. de la Ilustración 114, 18016 Granada, Spain.

³Maimonides Institute of Biomedical Research in Córdoba (IMIBIC), Cellular Therapy Unit, Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain.

⁴Department of Medicinal and Organic Chemistry, Faculty of Pharmacy, University of Granada, Campus Cartuja, 18071 Granada, Spain.

⁵Department of Hematology, ICMHO, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.

*Share authorship

Corresponding author: Francisco Martin.

Gene and Cell therapy Unit, Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Avda. de la Ilustración 114, 18016 Granada, Spain.

francisco.martin@genyo.es

Running title: TCR-like LVs for improved CAR-T

- 1   **List of abbreviations**
- 2   ATMP: advanced therapy medical product.
- 3   B-ALL: B-acute lymphoblastic leukaemia.
- 4   CAR: Chimeric Antigen Receptor.
- 5   CMV: Cytomegalovirus.
- 6   eGFP: enhanced green fluorescent protein.
- 7   EF1 α : Elongation Factor 1- α
- 8   EMA: European Medicine Agency.
- 9   FDA: Food and Drug administration.
- 10   LVs: Lentiviral vectors.
- 11   LTR: long-terminal repeats
- 12   MSCV: murine stem cells virus
- 13   NTD: non-transduced cells.
- 14   R/R: relapsed/ refractory.
- 15   ScFv: Single chain variable fragment.
- 16   SFFV: Spleen focus forming virus.
- 17   TCR: T cell receptor.
- 18   TCM: T central memory.
- 19   TEF: T effectors.
- 20   TEM: T effectors memory.
- 21   TN/SCM: T naïve/stem cell memory.
- 22   TRAC: T cell receptor (TCR) constant alpha locus
- 23   WAS: Wiskott-Aldrich syndrome.

1 ABSTRACT

2 **Background.** Chimeric antigen receptor (CAR) T cells directed against CD19 have achieved
3 impressive outcomes for the treatment of relapsed/refractory B lineage lymphoid neoplasms.
4 However, CAR-T therapy still has important limitations due to severe side effects and the lack
5 of efficiency in 40-50% of the patients. Most CARs-T products are generated using retroviral
6 vectors with strong promoters. However, high CAR expression levels can lead to tonic
7 signalling, premature exhaustion and over-stimulation of CAR-T cells, reducing efficacy and
8 increasing side effects. TCR-like expression of the CAR through genome editing resulted in
9 enhanced anti-tumour potency, reducing tonic signalling and improving CAR-T phenotype. In
10 this manuscript, we searched for LVs that mimic the TCR expression pattern as a closer-to-
11 clinic alternative for the generation of improved CAR-T cells.

12 **Methods.** Different LVs containing viral and human promoters were analysed to select those
13 that closely mimic a TCR-like kinetic profile upon T-cell activation. WAS gene proximal
14 promoter-driven LVs (AW-LVs) were selected to express a second generation 4-1BB α CD19
15 CAR (ARI-0001) into T cells to generate AWARI CAR-T cells. TCR-like AWARI and EF1 α -
16 driven ARI CAR T cells were analysed for *in vitro* and *in vivo* killing efficiency using
17 leukaemia and lymphoma cellular models. Tonic signalling, exhaustion markers and phenotype
18 were determined by flow cytometry. Large-scale automated manufacturing of AWARI CAR-T
19 cells was performed in a CliniMACs Prodigy bioreactor.

20 **Results.** Our data showed that LVs expressing the transgene through the WAS gene proximal
21 promoter mimic very closely the TCR (CD3) expression pattern kinetic upon TCR stimulation
22 or antigen encounter. Compared to EF1 α -driven ARI CAR-T cells, AWARI CAR-T cells
23 exhibited a higher proportion of naïve/stem cell memory T cells with less exhausted phenotype
24 after efficient killing of CD19+ cells both *in vitro* and *in vivo*. AWARI CAR-T cells also
25 showed lower tonic signalling and reduced secretion of pro-inflammatory cytokines and were
26 efficiently manufactured in large-scale GMP-like conditions.

1 **Conclusions.** WAS-gene-promoter driven LVs can be used to generate physiological 4-1BB-
2 CAR-T cell products with lower tonic signalling, improved phenotype and a safer profile. We
3 propose the use of TCR-like LVs as an alternative to strong-promoter driven LVs for the
4 generation of CAR-T products.

5 **Keywords**

6 CAR-T; Physiological expression; TCR-like expression; Lentiviral vectors; tonic signalling;
7 Pro-inflammatory cytokines, Exhaustion; CAR silencing; WAS gene promoter; Stem Cell
8 Memory T cells.

10 **BACKGROUND**

11 Chimeric antigen receptor (CAR) T cells have become one of the most promising approaches
12 for the treatment of cancer in particular for B lineage lymphoid neoplasms using α CD19-CAR-T
13 cells, as emphasized with four FDA/EMA-approved Advance Therapy Medicinal Products
14 (ATMPs): tisagenlecleucel (Kymriah, Novartis), axicabtagene ciloleucel (Yescarta, Kite-Gilead),
15 brexucabtagene autoleucel (Tecartus, Kite-Gilead) and lisocabtagene maraleucel (Breyanzi,
16 Bristol Myers Squibb). However, in spite of the impressive results of α CD19-CAR-T cells,
17 there are still several aspects that must be improved. Aggressive severe side effects due to CAR-
18 T overstimulation, such as cytokine release syndrome (CRS) and neuroinflammation are
19 common among treated patients and can lead to fatal outcomes. Furthermore, sustained
20 complete remissions range from 62% to 42% for patients treated with commercial ATMPs,
21 evidencing much room for improvement¹.

22 Different works have uncovered the importance of controlling CAR expression levels at the
23 surface of the CAR-T cells in order to optimize its therapeutic activity²⁻⁴. In spite of this, all
24 four approved ATMPs approved and most of those that are been tested in ongoing clinical trials
25 use autologous T cells transduced with retroviral vectors expressing a α CD19-CAR through
26 constitutive, strong promoters such as the human EF1 α and the murine stem cell virus LTR

(MSCV). High CARs concentrations on the T cell surface can result in spontaneous clustering of the CARs (independent of the ligand) leading to tonic-signalling^{4,5}. This tonic signalling can affect safety (pro-inflammatory cytokines secretion in non-target tissues) and efficacy (premature exhaustion due to continuous proliferation) of CAR-T cells^{3,5}. Furthermore, high-density and constitutive CAR presence on the T cell surface can also lead to overstimulation upon antigen recognition that also affect safety (excess of pro-inflammatory cytokine secretion) and efficacy (early exhaustion, apoptosis and loss of T_{N/SCM} phenotype) of the CAR-T cells^{2,3}. In this direction, Eyquem et al. generated CAR-T cells expressing the α CD19-28 ζ CAR through the endogenous T cell receptor constant alpha chain (TRAC) locus using CRISPR/Cas9². In this manuscript, the authors concluded that tight transcriptional regulation of CAR expression, lowering CAR levels upon target binding and recovering 1-3 days later, was critical for optimal CAR-T performance. However, despite the great potential of genome editing tools for therapeutic applications, there are still several technological and safety issues that need to be solved before the approval of genome edited cells as ATMPs.

Contrary to genome editing tools, lentiviral vectors (LVs) derived from HIV-1 have already been approved by the FDA and EMA (Kymriah, Breyanzi and Zynteglo). Latest generation LVs are very resistant to transgene silencing^{6,7}, and allow the control of the transgene through physiological or drug inducible promoters⁸⁻¹³. We therefore searched for LVs that express transgenes on T cells following a TCR expression kinetic. Since the TRAC promoter in human mature T cells is not well defined, we focus in a well-defined promoter that controls the expression of the WASP protein, which is involved in the formation of the immunological synapse and in translating TCR signals to several T cells functions^{14,15}. We reason that WAS-promoter driven LVs^{8,11,16} could be an interesting option to express CARs due to their moderate expression levels and the functional relationship with the TCR. Here we showed that, indeed, WAS-promoter driven LVs partially mimicked the TCR expression kinetic both in eGFP- and CAR-expressing LVs, with a small down-regulation upon stimulation and recovering basal levels in 5-7 days. Based on these data, we generated TCR-like CAR-T cells using LVs and

1 analysed potential improvements compared to standard CAR-T cells expressing the CAR
2 through strong promoters. TCR-like expression of a α CD19-CAR lead to lower tonic signalling
3 in the absence of antigen as well as a better response in its presence, with lower exhaustion
4 markers, lower proinflammatory cytokine secretion and improved phenotype both *in vitro* and
5 *in vivo*.

6 **MATERIALS and METHODS**

7 **Cell culture**

8 Nalm6 (ATCC® CRL-3273), Namalwa (ATCC® CRL-1432), Jurkat (ATCC® TIB-152), HL-
9 60 (ATCC® CCL-240) and HEK-293T (ATCC® CRL-11268) cells were cultured as described
10 elsewhere. Namalwa and Nalm6 were modified to express enhanced GFP (eGFP) and
11 Nanoluciferase (NanoLuc) using the SELWP, as described previously¹⁷.

12

13 **Human samples**

14 Primary T cells were isolated from fresh or frozen apheresis products obtained from healthy
15 donors at the Hematology Department of the Hospital Universitario Reina Sofía (Córdoba,
16 Spain). All donors gave their written informed consent and the study was performed according
17 to the guidelines of the local ethics committee and complies with the requirements regarding
18 quality and safety for donation, obtaining, storage, distribution, and preservation of human cells
19 and tissues under the Spanish specific regulation (RD-L 9/2014). Pan-T cells were isolated by
20 negative selection using immunomagnetic beads (Pan T cell Isolation Kit, Miltenyi Biotec) and
21 following MACSEXPRESS Separator (Miltenyi Biotec) or AutoMACs Pro Separator's (Miltenyi
22 Biotec) protocol and cultured in TexMACS (Miltenyi Biotec) supplemented with 20 UI/ml of
23 IL-2 (Miltenyi Biotec). T cells were activated with T Cell TransAct (Miltenyi Biotec).

24 **Plasmid constructs**

25 To construct the SELWP vector, a self-inactivated (SIN) LV expressing eGFP and NanoLuc
26 under the spleen focus-forming virus (SFFV) promoter, an eGFP-P2A-NanoLuc (NanoLuc

1 sequence obtained from GeneBank accession: JQ437370. Nucleotides 100-616) flanked by
2 AscI/SbfI restriction sites was designed and synthesized by Genscript (Genscript USA Inc. NY,
3 U.S.A). The eGFP-P2A-NLuc was cloned into the SEWP LV¹⁸ by standard molecular biology
4 techniques to obtain the SELWP.

5 We used self-inactivated LVs-driven eGFP already available in our laboratory. SE¹⁶, CEWP¹⁰
6 and EFEWP (our laboratory) driving eGFP under the control of SFFV, cytomegalovirus, and
7 EF1a promoters, respectively. WAS-promoter based LVs: WE-LVs harbours 0.5kb of the WAS
8 proximal promoter¹⁶, and the AWE-LVs include 0.5kb of the WAS proximal promoter and 0.38
9 kb of the alternative promoter⁸.

10 For AWARI LVs generation, the AW promoter were obtained from the AWE⁸ by ClaI / BamHI
11 and inserted into the ARI-0001 plasmid¹⁹, replacing the EF1 α promoter.

12 **Lentiviral vector production and titration**

13 Lentiviral vectors were generated by co-transfection of HEK-293T cells with the plasmid of
14 interest, the plasmid pCMVDR8.91 and the p-MD-G plasmid as previously described¹². LVs
15 were concentrated by ultracentrifugation at 90.000g for 2h at 4°C, resuspended in TexMACs
16 and stored at -80°C. LVs titers were determined by transducing Jurkat cells with different
17 dilutions of viral supernatant. Percentage of positive cells was determined by flow cytometry
18 and transducing units per ml (TU/ml) were estimated according to the formula: (10⁵ plated cells
19 $\times$ % of positive cells)/ml of LV.

21 **T cell transduction**

22 Activated primary T cells were transduced with the different LVs at a multiplicity of infection
23 (MOI) of 10 through spinoculation (800 x g for 60 min at 32°C). Media was exchanged after 5
24 hours of incubation. At 4-6 days after transduction, the percentage of transduced cells was
25 determined by flow cytometry.

1 Expression pattern analysis of LVs on T cells

2 For T cells transduced with eGFP-LVs, 10^5 T cells were stimulated with TransAct (Miltenyi
3 Biotec) after 10 days of the initial activation for transduction. Similarly, 10^4 transduced CAR-T
4 cells were stimulated with 10^4 CD19+ Namalwa-GFP-NLuc cells in order to simulate the
5 CAR/TCR signalling axis in U-bottom 96-wells plates. eGFP or CAR expression was
6 determined at different time-points after stimulation. Cells were stained and fixed with 2% PFA
7 prior FACS acquisition. Expression was indicated as the ratio of MeFI of positive population
8 against the MeFI of non-transduced total population. Fold change indicates the ratio of
9 expression or percentage related to those values at 0h.

10 Flow cytometry

11 CAR expression was determined with a biotin-conjugated goat anti-murine Fab SP-longer
12 Spacer IgG (Jackson ImmunoResearch) and APC-conjugated streptavidin (ThermoFisher). For
13 human T cell phenotyping the following mAbs were used: CD45RA-PE/FITC (HI-100),
14 CD62L-PE-Cy7 (DREG56), CD3-PerCP-Cy5/APC-780 (OKT3), PD1-APC (MIH4), LAG-3-
15 PE (3DS223H), TIM-3-APC-Cy7 (F38-2E2) all from eBioscience (ThermoFisher). Tonic
16 signalling was determined by intracellular staining with pCD3z-PE (Tyr142, 3ZBR4S) and Fix
17 & Perm Kit (Nordic Bio). Samples were acquired on a FACSCantoII cytometer. FlowJo
18 software (TreeStar) was used for data analysis.

19 Cytokine secretion of CAR-T cells

20 To analyse cytokine production after T cells stimulation, 5×10^4 CAR-T cells were co-cultured
21 with Namalwa-GFP target cells at ratio 1:1 in TexMACs without any supplement. Supernatants
22 were collected after 24h and frozen at -80°C . TNF α and IFN γ were measured with anti-human
23 TNF- α Ready-SET-Go! Kit of Affymetrix (eBioscience) and ELISA MAX Deluxe Set
24 (Biolegend) respectively following manufacturer's instructions.

25

1 Cytotoxicity assay

2 Target cells (CD19+), such as Namalwa and Nalm-6 cells expressing GFP-Nluc, and non-target
3 cells (CD19-) HL60 cells (unlabelled), were co-cultured at a concentration of 5×10^3 cells per
4 well in duplicate in 96-well U-bottom plates, and incubated with T cells at various effector-
5 target (E:T) ratios (0.5:1, 1:1, 2:1) in non-supplemented TexMACs during 16h or 48h as
6 indicated. Percentage of lysis was determined by flow cytometry related to basal lysis produced
7 by non-transduced T cells. Specific lysis was determined as follows: $1 - (\% \text{CD19}^+ / \% \text{HL-60 in}$
8 $\text{CAR-T cells condition} / \% \text{CD19}^+ / \% \text{HL-60 in NTD condition}) \times 100$.

9 *In vivo* xenograft animal model and bioluminescence analysis

10 10 to 12-weeks-old NOD/scid-IL-2Rnull (NSG) mice were inoculated intravenously with 3×10^5
11 Namalwa-GFP-NLuc cells per mice, and three days later, mice were randomly infused with
12 CAR-T cells (5×10^6 or 10×10^6), non-transduced T cells (5×10^6 or 10×10^6) or PBS in the tail's
13 vein. Re-challenge was assessed by re-inoculating intravenously a new dose of Namalwa-GFP-
14 Nluc cells. Our experiments are based on a modified randomized block design in which each
15 block receives more than one treatment at different periods. Subjects were randomly assigned to
16 receive the different treatments (PBS, T cells or CAR-T cells). This will allow a comparison
17 between the different treatment groups in pairs (each one compared to the control and each one
18 compared to each other). For the estimation of the sample size in each experiment, we
19 calculated the sample size necessary to obtain a $p \geq 0.05$ to be of $n \geq 5$ for controls/CAR-T
20 comparison and an $n \geq 8$ for AWARI/ARI comparisons based on Mayer et al²⁰. For
21 bioluminescence analysis, furimazine (Nano-Glo, Promega) was diluted at 1/60 in PBS and
22 injected intraperitoneally immediately prior to acquisition on an IVIS Spectrum analyzer
23 (Caliper, Perkin Elmer). Images were acquired during 180s, open field, and analysed using the
24 Living Image 3.2 (Perkin Elmer) or AURA Imaging Software 3.2 (Spectral Instruments
25 Imaging). Mice were sacrificed if experiencing a weight loss greater than 20% or at the
26 indicated days. Samples of blood, bone marrow, liver, spleen and brain were collected. Blood
27 was extracted and diluted 1/5 in EDTA. Cells were obtained from liver and spleen by

1 mechanical disruption and from bone marrow by the perfusion of both femurs and tibias.
2 Brain's cells were obtained after Percoll-gradient separation. Percentage of surviving Namalwa-
3 GFP-Nluc and T cells (hCD3+) were determined by FACS in the singlet's gate and then in
4 "human cells" gate, which was previously established after acquiring an artificial mixture of
5 Namalwa cells and human T cells used as control.

6 **GMP-like manufacturing of CAR-T cells on CliniMACs Prodigy**

7 Large scale manufacturing of CAR-T cells on CliniMACs Prodigy was carried out under GMP-
8 like conditions into Gene-Cell Therapy cleanrooms of Cell Therapy Unit of Hospital
9 Universitario Reina Sofía (Córdoba, Spain). Two different apheresis from a healthy donor was
10 thawed and around 100×10^6 T cells were inoculated into the CliniMACs prodigy bioreactor
11 (Miltenyi Biotec). CD4 and CD8 cells were selected with CD8 and CD4 Reagent (Miltenyi
12 Biotec), cultured with IL-7/IL-15 (Miltenyi Biotec) and activated with α CD3/ α CD28 GMP T
13 cell TransAct (Miltenyi Biotec). At day 2 of the process, these cells were transduced with
14 AWARI-LVs (MOI=5). Cells were cultured in TexMACs GMP medium containing GMP-grade
15 IL-15 and IL-7 (Miltenyi Biotec) for 9 or 10 days. Final product was collected with 100ml of
16 NaCl 0,9% + 0,5% human serum albumin (HSA).

17 Cells were stained with CD3-APC, CD4-FITC, CD8-APC Vio770, CD14-PE Vio770, CD45-
18 Vioblue (Miltenyi Biotec). To assess the efficiency of transduction CAR-T cells were stained
19 with CD-19 Biotin and Anti-biotin PE (Miltenyi Biotec). Viability was tested by using 7AAD
20 (Miltenyi Biotec). Phenotype was determined with CD45RA-APC (HI100) and CCR7-BV421
21 (2-L1-A RUO) from BD Pharmingen. Cells were acquired on a MACsQuant cytometer
22 (Miltenyi Biotec) and analyzed with MACsQuantify Analysis Software (Miltenyi Biotec).

23 **Data analysis**

24 Statistical analyses were performed using GraphPad 1.6 software (GraphPad Software Inc., La
25 Jolla, CA). Data were expressed as the mean $\pm$ SEM. Each performed statistical test was

indicated in every figure caption. Survival curves were constructed using the Kaplan–Meier method.

RESULTS

WAS promoter-driven LVs mimic the TCR expression pattern upon T-cell activation

As LVs have already been approved by EMA and the FDA, LVs expressing the CARs with a similar kinetic than the TCR (TCR-like LVs) could be a real alternative to existing LVs to generate more potent and safer CAR-T cells. We first investigated whether WAS-promoter-driven LVs could have a more physiological expression pattern compared to current LVs used for CAR-T cells generation. We generated eGFP-expressing LVs particles from two different WAS-promoter-driven LVs (**Fig. 1A**, WE and AWE)^{8, 16} and three LVs driven by strong promoters (**Fig. 1A**, CEWP, SE and EFEWP).

In order to analyse if the WAS-promoter-driven LVs mimic the TCR expression pattern, we first studied the CD3 expression levels (**Fig. 1B and Fig. S1a**) of primary human T cells after stimulation with α CD3/ α CD28 nanomatrix and CD19+ cells (in CAR+ cells, **Fig 1B and Fig S1b**) at different time-points. In parallel, T cells transduced with the different eGFP-expressing LVs were stimulated and analysed by flow cytometry as described in **Fig. 1A**. As it has been reported previously², CD3 expression in T cells decreased soon after stimulation reaching minimal expression at 24h/48h at both protein and mRNA levels and recover basal levels after 5-7 days (**Fig 1B, S1a**). Contrary to the CD3 expression pattern, all LVs harbouring constitutive-strong promoters (EF1 α (EFEWP), SFFV (SE) and CMV (CEWP)), behaved in an opposite manner, increasing eGFP expression soon after T cell stimulation (**Fig. 1C-top panels, 1D and 1E-orange line**). Interestingly, WAS-promoter driven LVs partially mimicked the TCR expression kinetic, down-regulating eGFP expression upon stimulation that peak at 48h and recover basal levels after 7 days (**Fig. 1C-bottom panels, 1E-blue and green lines**).

1 We next investigated whether CARs expressed by WAS-promoter driven LVs also followed a
 2 TCR-like kinetic. We constructed the AWARI LV (see M&M for details) based on the ARI-
 3 0001 LV backbone²¹, a CAR19-BBzz recently approved as ATMP in Spain, which uses the
 4 A1B6 clone as scFv (Fig. **1F**). We then generated ARI and AWARI CAR-T cells using the ARI
 5 and AWARI LVs and analysed their CAR expression kinetic upon activation with CD19+ cells
 6 (**Fig 1G-left, 1H and S1B-left**) or α CD3/ α CD28 (**Fig 1G-right, 1I and S1B-right**). Interestingly,
 7 AWARI CAR-T cells showed a down-regulation of CAR levels after antigenic stimulation and
 8 a recovery after 48h (**Fig. 1H, 1I, blue line; Fig. 1G, bottom panel**), while ARI CAR-T cells
 9 showed a clear increment on CAR levels after T cell activation (**Fig. 1H, 1I, green lines, Fig.**
 10 **1G, top panel**). A similar behaviour was also observed when using a third generation α CD19-
 11 CAR-28BBzz (**Fig S1C, S1D**). Altogether, our results showed that the AW-LVs can be used to
 12 generate CAR-T cells expressing the CAR in a TCR-like manner.

13

14 **TCR-like expression of CAR prevents exhaustion and control proinflammatory cytokines** 15 **secretion upon antigen exposure *in vitro***

16 We next compared the behaviour of 2nd generation ARI versus AWARI CAR-T cells. First, we
 17 measured basal levels of exhaustion markers (LAG-3, PD1, Tim3) (**Fig. 2A**) and tonic
 18 signalling (phospho-CD3z) (**Fig. 2B**) in a CD19-independent context. AWARI CAR-T cells
 19 expressed significant lower levels of LAG-3 and Tim3 (and also a trend for PD1) (**Fig. 2A**) and
 20 less phosphorylation of CD3z (**Figure 2B**). Both CAR-T cells efficiently killed CD19+ Nalm6
 21 (B-ALL derived) and Namalwa (Hodgkin's lymphoma derived), without significant differences
 22 (**Fig. 2C**). Interestingly, LAG-3 expression levels were significantly lower in AWARI
 23 compared to ARI CAR-T cells after killing Namalwa cells (**Fig. 2D, right**). In addition, AWARI
 24 CAR-T cells secreted lower levels of TNF α and IFN γ compared to ARI cells (**Fig. 2E**),
 25 indicating a more controlled proinflammatory activity. We also observed a tendency of
 26 increased stem memory T cells (CD45RA+CD62L+) population in AWARI versus ARI CAR-T
 27 cell (but not statically significant, **Figs. S2D, S2E**). Finally, similar observations were found

1 when 3rd generation CARs (CAR19-28BBzz) were expressed with the AW-LVs in terms of
2 lower tonic signalling (**Fig S2A**) and milder IFN γ secretion (**Fig. S2B**).

3

4 **AWARI CAR-T cells are as efficient as ARI CAR-T cells eradicating CD19+ tumour cells**
5 ***in vivo* and maintain a more stem-like phenotype.**

6 *In vitro* cytotoxicity experiments only represent a direct-short term activity of CAR-T cells. We
7 therefore performed a direct comparison of the anti-tumour activity of ARI versus AWARI
8 CAR-T cells in a xenograft mice model of human lymphoma using two different CAR-T doses
9 and a re-challenge after first lymphoma cells clearance (**Fig. 3A**, See M&M for details). Both
10 CAR-T cells efficiently eliminated Namalwa tumour cells in treated mice with both doses (**Figs.**
11 **3B, 3C** and **Fig. S3A**). However, a small amount of Namalwa cells (less than <5%) were
12 detected in liver of some ARI-mice and in brain of some AWARI-mice treated with the low
13 dose (**Fig. 3C**, left panels). Importantly, CAR expression driven by the two vectors was
14 maintained in all the organs after sacrifice (**Fig. 3D**), even with a second-challenge, when
15 compared to those ex-vivo levels prior to infusion (**Fig. S3B**), indicating no promoter silencing.

16 After showing the same therapeutic efficacy, we investigated potential differences in CAR-T
17 cell phenotype after tumour clearance. Interestingly, AWARI-CAR-T cells showed a higher
18 proportion of memory (T_{CM}: CD45RA-CD62L+) and stem memory (T_{SCM}: CD45RA+CD62L+)
19 (**Fig. 3D**) cells in spleen, bone marrow (BM), blood and liver when compared to ARI-treated
20 mice (**Fig.3E, 3F**). Specially after re-challenge (inner circle, **Fig. 3E**), T_{SCM} population of
21 AWARI-CAR-T cells was increased in spleen and liver and T_{CM} subset in BM and brain. In
22 order to further characterize the potential differences, we cultured the cells from processed
23 spleens during 48h *in vitro* with 200 UI/ml of IL-2 in TexMACs medium (**Fig. 3G**), and we
24 confirmed an increment in T cell memory populations in AWARI-derived spleens (**Fig. 3H, 3I**)
25 and a tendency to have lower expression of exhaustion markers (PD1+LAG3+) (**Fig. 3H, 3J**).

26

1   **Large-scale semi-automated manufacturing of AWARI CAR-T cells**

2   Before translation of AW-LV to ATMP production for clinical applications, it is important to
3   demonstrate their performance for large-scale automated manufacturing. We therefore used
4   laboratory grade AWARI LVs to generate two batches of CAR-T cells (#01 and #02) in the
5   CliniMACs Prodigy Bioreactor (Miltényi Biotec) under GMP conditions (see M&M). Samples
6   at days 7 and 10 for batch #01, and 6 and 9 days for batch #02 (**Fig. 4A**) were collected to study
7   CAR expression (**Fig. 4B**), viability, expansion (**Fig 4C**), CD4/CD8 ratio (**Fig. 4D**), phenotype
8   (**Fig. 4E**), and *in vitro* lytic activity (**Fig. 4F**). In both productions processes, cells were
9   efficiently expanded, with more CD4⁺ than CD8⁺ CAR⁺ cells and prominent T_{N/SCM} (CCR7⁺
10   CD62L⁺) subset (44,85 ±0.07%) at day 7 or day 6, that were drastically reduced at final day of
11   the production (16,55 ±13.93%), turning into T_{CM} cells but with minimal effector and effector
12   memory populations (**Fig. 4E**). As described for other CAR-T cell products, lower expansion
13   times rendered more potent AWARI CAR-T cells (**Fig. 4F**). All these results point out to the
14   AWARI LVs as a valuable tool for a future clinical trial, although improvements in its lentiviral
15   backbone could further increase transduction efficacy in order to lower costs and time of
16   production.

17

18   **Large-scaled manufactured AWARI CAR-T cells products are highly efficient for tumour** 19   **clearance and maintain good levels of T_{N/SCM} cells *in vivo*.**

20   Finally, we performed a detailed analysis of large-scale manufactured AWARI CAR-T cells in
21   terms of their *in vivo* anti-tumour efficacy and their phenotype after isolation from treated mice
22   (**Fig. 5**) for both #01 (blue dots) and #02 (green dots) CliniMACS batches. Anti-tumour activity
23   of both AWARI CAR-T cells products were analysed in the Namalwa xenograft mice model as
24   depicted in Fig 5A. Survival (**Fig. 5B**) and tumour progression (**Figs. 5C and 5D**) were
25   monitored up to 28-30 days post-treatment showing a strong anti-tumour activity of the AWARI
26   CAR-T cells with 100% survival and undetectable tumour cells in treated mice (**Figs. 5C, 5D**
27   and **Fig. S4A**). Control PBS and NTD- inoculated mice developed the disease at similar rates

1 and the majority required to be sacrificed for compassionate reasons at days 13-16. At this time
2 point, the stemness of human CAR-T cells of two AWARI-treated mice (**Fig. 5F** top panel,
3 **S4C**) in #01 experiment was clearly maintained. New Namalwa cells were inoculated in
4 AWARI -T cells-treated mice and also in new mice (“New PBS”). Re-challenged AWARI-mice
5 remained tumour-free through the duration of the experiment as did the follow-up group.
6 Similar results were observed in both productions (**Fig. 5C, 5D, S4A**). The percentage of CAR+
7 cells (**Fig 5E**) was maintained before (*ex-vivo*) and after *in vivo* elimination of Namalwa cells in
8 the xenograf model with a slight increase in some of the organs (**Fig. S4b**). Importantly, the
9 phenotypic analysis confirmed the presence of a high proportion of T_{SCM}/T_{CM} populations (**Fig.**
10 **5E, 5F, S4D**) at the end point of rechallenged and non-rechallenged mice. However, a
11 significant reduction of these populations was observed from day 13 to day 30 (**Fig. 5F top**
12 **panel, S4C**). This data confirmed the *in vitro* (**Fig. S2**) and *in vivo* (**Fig. 3**) results showing that
13 the expression of the ARI-CAR19-BBzz through a TCR-like promoter (AWARI-CAR-T cells)
14 maintains the proportion of T_{SCM}/T_{CM} CAR-T cells upon antigen encounter.

15

16

1 DISCUSSION

2 α CD19 CAR-T cells have achieved impressive therapeutic benefits in R/R B lineage lymphoid
3 neoplasms, leading to the approval of Kymriah, Yescarta, Tecartus and Breyanzi and over 800
4 clinical trials around the globe. Most of these studies have used autologous T cells that are gene
5 modified by retrovirus-based vectors to express the CAR through a strong promoter (often the
6 EF1 α or MSCV promoters). However, CAR-T therapy still has important limitations due to
7 severe side effects and the lack of complete cures in 40-62% of the CD19+ lymphomas¹ and
8 most solid tumours^{22,23}. Improvements in CAR structure (scFV, hinge/spacer, costimulatory
9 domains, bi-especific or multispecific CARs, etc) T cell composition or combinational therapies
10 have already shown improved results²⁴. New approaches to improve CAR-T efficacy and/or
11 safety include the control of CAR activity and or other molecules¹³ and mechanism to avoid
12 immune-reactions against the CAR-T cells²⁵.

13 There are several evidences indicating that high levels and continuous expression of the CAR
14 can be deleterious for the efficacy and safety of the CAR-T products²⁻⁴. The loss of efficacy
15 comes in part from the early exhaustion and/or apoptosis of the CAR-T cells due to an excess of
16 CAR signalling after antigen encounter²⁶. Strong and unregulated CAR expression also increase
17 tonic signalling in the absence of target antigen⁴ promoting exhaustion^{3, 5}. On the other side,
18 safety issues due to CAR overexpression relates to the increased antigen-independent tonic
19 signalling and to over-stimulation of CAR-T cells that generate CRS. Using genome editing
20 technologies, Eyquem et al. demonstrated that TCR-like expression of CARs resulted in lower
21 tonic signalling, reduced CAR-T exhaustion and increased proportion of TSM/TN CAR-T cells,
22 resulting in improved anti-tumour activity². These authors also showed that low expression was
23 not enough to achieve optimal CAR-T products, concluding that a down-regulation of the CAR
24 upon antigen encounter was required for optimal CAR-T performance.

25 In this manuscript we investigated whether LVs can be used to obtain a TCR-like expression
26 kinetics that could also result in an improved CAR-T cell product. Our search for human

1 promoters that could mimic the TCR expression pattern pointed to the TRAC locus, however,
 2 the TRAC promoter in mature human T cells is not well defined. We therefore focus on the
 3 WAS gene promoter because WASP protein is only expressed in hematopoietic cells, is involved
 4 in the formation of the immunological synapse and acts as an adaptor of TCR signals^{14,15}. We
 5 have previously developed different WAS-gene based promoters and identified the AW
 6 promoter, harbouring fragments from the alternative and proximal promoter, as the best option
 7 to express transgenes in hematopoietic cells^{8, 11, 16}. Here we showed that, indeed, WAS-promoter
 8 driven LVs (AW-LVs) partially mimicked the TCR expression kinetic, with a small down-
 9 regulation upon stimulation and recovering basal levels in 5-7 days.

10 Based on the ability of AW-LVs to mimic TCR expression pattern on T cells, we investigated
 11 whether 4-1BB-CAR-T cells generated with this “physiological” LVs have a better behaviour
 12 compared to that generated with LVs harbouring strong or viral promoters. Although in terms of
 13 *in vitro* or *in vivo* anti-tumour activity we could not detect significant differences with EF1 α -
 14 driven CAR-T cells, AW-CAR-T cells exhibited lower tonic signalling and a better phenotype
 15 after efficient killing of CD19+ cells, with reduced secretion of pro-inflammatory cytokines.
 16 These data is largely in agreement with the observations of Eyquem et al. using genome editing
 17 technologies to express the CAR through the TRAC locus². However, these authors also showed
 18 improved *in vivo* anti-tumour activity². The differences in the tumour model (Nalm6 versus
 19 Namalwa) as well as in the CAR signalling domain (CD28 versus 4-1BB) and scFv (FMC63
 20 versus A3B1) could explain the observed differences. Indeed, the potential deleterious effects of
 21 CAR over-expression and tonic signalling are highly influenced by the CAR configuration^{2, 4}.
 22 For instance, replacing CD28 with the 4-1BB costimulatory domain reversed exhaustion in
 23 CAR T cells and improved its persistence and therapeutic efficacy²⁷. The good behaviour of
 24 EF1 α -driven 4-1BB-CARs T cells and the experimental limitations derived by the graft versus
 25 host disease (GVHD) caused by the administration of the CAR-T cells can explain the absence
 26 of increased therapeutic efficacy in our animal models.

1 In spite of the good behaviour of 4-1BB-CARs, Gomes-Silva et al demonstrated that very high
2 expression levels of 4-1BB-CARs also lead to apoptosis and limit CAR-T cells expansion⁴. The
3 same authors also showed that lowering its expression levels by using EF1 α -driven LVs instead
4 of LTR-driven Ψ -retroviral vector, improved phenotype, expansion potential and therapeutic
5 efficacy. These studies showed that EF1 α -driven LVs already generate a good CAR product for
6 some 4-1BB-CARs. Here we show that TCR-like expression can further improve 4-1BB-CAR-
7 T products, in particular for the ARI-0001, by maintaining a better phenotype and controlling
8 tonic signalling and pro-inflammatory cytokine secretion.

9 An important aspect to consider in CAR-T cells is the potential side effects due to
10 overstimulation and/or inadequate stimulation. Severe CRS (grades 3 or 4) is an important
11 hallmark in CD19+ that can compromise efficacy and lead to life-threatening conditions^{28,29}.
12 Upon tumour cell encounter, CAR-T cells release different pro-inflammatory cytokines such as
13 TNF α , IFN γ , IL-1 and GM-CSF that leads to macrophage recruitment and activation causing a
14 dangerous cytokine storm involving IL-6 and GM-CSF^{30,31}. It has also been demonstrated that
15 activation of macrophages through CD40/CD40L, CD69 and LAG-3 also contributes to massive
16 activation²⁹. Although CRS can be managed with corticosteroids and anti-IL6R (Tocilizumab),
17 these interventions also block T cell activation compromising CAR-T efficacy²⁹. In this
18 manuscript, we have shown that CAR-T cells generated with AW-LVs exhibit a milder
19 secretion of TNF α and IFN γ after tumour cells encounter. In addition, we noted that LAG-3
20 expression was reduced after Namalwa interaction which suggests that AW-CAR-T cells could
21 lower the risk of CRS.

22 We finally investigated the feasibility of generating a viable CAR-T cell product for clinical
23 translation. Here, we have demonstrated that it is feasible to generate TCR-like CAR-T cells in
24 a CliniMACs Prodigy, with high cell viability, predominant stem and CM populations and
25 potent *in vitro* and *in vivo* anti-tumour activity. In contrast and consistent with our comparative
26 results, ARI-0001 generated more memory and effector memory population¹⁹, highlighting
27 another potential advantage of AW-CAR-T cells during the manufacturing process. On the other

1 hand, the efficacy of transduction was lower compared to ARI (~ 18.4% vs ~30.6%), suggesting
2 that a future optimization of the AWARI LV backbone could further improve the manufacturing
3 process of AW-CAR-T cells.

4 Taken all together, we propose the use of AW-LVs as an alternative platform for the
5 manufacturing of CAR-T cells in order to provide better efficacies and/or safety of the final
6 products. The final benefits of expressing different CARs through the AW promoter will need to
7 be determined in each case.

8

9 **Conclusions**

10 In this work we showed that LVs expressing the transgene through the WAS gene proximal
11 promoter mimic very closely the TCR expression pattern kinetic in T cells. 4-1BB-CAR-T cells
12 generated with WAS-promoter-driven LVs (AWARI CAR-T) exhibited a higher proportion of
13 Naïve/Stem Cell Memory T cells, less exhausted phenotype, lower tonic signalling and reduced
14 secretion of pro-inflammatory cytokines compared to EF1-driven ARI CAR-T. Finally, AWARI
15 CAR-T cells were efficiently manufactured in large-scale GMP-like conditions. Altogether, our
16 data showed that the AW-LVs can be used to generate improved, physiological 4-1BB-CAR-T
17 cell products and propose these LVs as efficient tools for the generation of clinical-grade TCR-
18 like CAR-T cells.

19

20 **DECLARATIONS**

21 **Ethics approval and consent to participate**

22 All donors from the Haematology Unit of Hospital Reina Sofía, Córdoba (Spain) gave their
23 written informed consent and the study was performed according to the established guidelines
24 of in the approved by the Regional Government Junta de Andalucía-Consejería de Salud (date

1 of approval: 22/02/2019, signed by D^a Cristina Lucía Dávila Fajardo as secretary of the
2 Research Ethics Committee), that comply with the requirements regarding quality and safety for
3 donation, obtaining, storage, distribution, and preservation of human cells and tissues under the
4 Spanish specific regulation (RD 9/2014) and International Conference of Good Clinical
5 Practice. All the experiments involving animals were performed according to a protocol
6 approved by the Institutional Animal Care and Use Committee of the University of Granada
7 (13/12/2016/181) were in accordance with the European Convention for the Protection of
8 Vertebrate Animals used for Experimental and Other Scientific Purposes (CETS # 123) and the
9 specific Spanish law (R.D. 53/2013). Subjects were randomly assigned to receive the different
10 treatments and sample size estimation was calculated based on Mayer et al²⁰.

11 **Consent for publication**

12 All the authors consent the publication of this manuscript.

13 **Availability of data and material**

14 All data relevant to the study are included in the article or uploaded as online supplemental
15 information. Figures were created with Biorender.com.

16 **Competing interests**

17 FMM, MTM, NMP, PM and KB are inventors of a patent for AW promoter for CAR-T cells
18 applications. P.J.L is contractually associated to LentiStem Biotech, a Spin-Off company that
19 has the license of that patent. The rest of the authors declare that the research was conducted in
20 the absence of other commercial or financial relationships that could be construed as a potential
21 conflict of interest.

22 **Funding**

23 This study was funded by the Spanish ISCIII Health Research Fund and the European Regional
24 Development Fund (FEDER) through research grants PI12/01097, PI15/02015, PI18/00337

(F.M.), PI18/00330 (K.B.) and PI17/00672 (P.M.); The CECEyU and CSyF of the Junta de Andalucía FEDER/European Cohesion Fund (FSE) for Andalusia provided the following research grants: 2016000073391-TRA, 2016000073332-TRA, PI-57069, PAIDI-Bio326, CARTPI-0001-201 (F.M.), PI-0014-2016 (K.B) and PEER-0286-2019 (P.M.), PE-0223-2018; The Ministerio de Ciencia, Innovación y Universidades (CDTI) to F.M. (00123009 / SNEO-20191072). K.B. and C.M held Nicolas Monardes contracts from regional Ministry of Health (#0006/2018 and C2-0002-2019 respectively). M.T.M., N.M.P and A.A.G. are funded by Spanish Ministry of Education and Science through fellowships FPU16/05467, FPU17/02268 and FPU17/04327 respectively. P.J.L is funded through an industrial doctorate MCI DIN2018-010180 to LentiStem Biotech. P.M is funded by Fundación Andaluza Progreso y Salud. M.C.G is funded by Spanish Ministry of Education and Science through fellowship GJ (PEJ-2018-001760-A). MDC is funded by the grant PE-0223-2018 CSyF of the Junta de Andalusia. M.T.M., N.P.M., P.L.J.L., M.C.G. and A.G.G. are PhD students from the Biomedicine Programme of the University of Granada (Spain).

Authors' contributions

MTM and NMP designed and performed experiments, analysed data and wrote the manuscript. PLJL performed and analysed experiments and critical review of the manuscript. PM contributed to animal experiments. MCG and KP contributed to T cells isolation and revised the manuscript. RJM and SN designed and produced CliniMACs Prodigy large scale CAR-T cells production process. RJM, SN and MDC performed the phenotypic characterization of CliniMACs-derived products. SSH and AAG contributed to AWARI LVs production. MC and MJ provided ARI-0001 LV and critical review. CM provided material and critical review. KB provided funding and critical review. CH provided funding and critical review of the manuscript. FM conceals the project, designed experiments, analysed data, provides the main funding and wrote the manuscript.

Acknowledgements

1 We thank Ana Fernández-Ibáñez for her support with the IVIS Spectrum Analyzer, Nieves
2 Álvarez for her help of ELISA assays. We also thank GENYO's supporting units.

3

4

5 **References**

6

- 7 1. Vitale C, Strati P. CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic
8 Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. *Front Oncol*
9 2020;**10**:849.
- 10 2. Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with
11 CRISPR/Cas9 enhances tumour rejection. *Nature* 2017;**543**(7643):113-17.
- 12 3. Frigault MJ, Lee J, Basil MC, et al. Identification of chimeric antigen receptors that mediate
13 constitutive or inducible proliferation of T cells. *Cancer Immunol Res* 2015;**3**(4):356-
14 67.
- 15 4. Gomes-Silva D, Mukherjee M, Srinivasan M, et al. Tonic 4-1BB Costimulation in Chimeric
16 Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. *Cell Rep*
17 2017;**21**(1):17-26.
- 18 5. Ajina A, Maher J. Strategies to Address Chimeric Antigen Receptor Tonic Signaling. *Mol*
19 *Cancer Ther* 2018;**17**(9):1795-815.
- 20 6. Benabdellah K, Gutierrez-Guerrero A, Cobo M, et al. A chimeric HS4-SAR insulator (IS2)
21 that prevents silencing and enhances expression of lentiviral vectors in pluripotent stem
22 cells. *PLoS ONE* 2014;**9**(1):e84268.
- 23 7. Naldini L, Trono D, Verma IM. Lentiviral vectors, two decades later. *Science*
24 2016;**353**(6304):1101-2.
- 25 8. Frecha C, Toscano MG, Costa C, et al. Improved lentiviral vectors for Wiskott-Aldrich
26 syndrome gene therapy mimic endogenous expression profiles throughout
27 haematopoiesis. *Gene Ther* 2008;**15**(12):930-41.
- 28 9. Romero Z, Torres S, Cobo M, et al. A tissue-specific, activation-inducible, lentiviral vector
29 regulated by human CD40L proximal promoter sequences. *Gene Ther* 2011;**18**(4):364-
30 71.
- 31 10. Benabdellah K, Cobo M, Munoz P, et al. Development of an all-in-one lentiviral vector
32 system based on the original TetR for the easy generation of Tet-ON cell lines. *PLoS*
33 *ONE* 2011;**6**(8):e23734.
- 34 11. Munoz P, Tristan-Manzano M, Sanchez-Gilabert A, et al. WAS Promoter-Driven Lentiviral
35 Vectors Mimic Closely the Lopsided WASP Expression during Megakaryocytic
36 Differentiation. *Mol Ther Methods Clin Dev* 2020;**19**:220-35.
- 37 12. Benabdellah K, Munoz P, Cobo M, et al. Lent-On-Plus Lentiviral vectors for conditional
38 expression in human stem cells. *Sci Rep* 2016;**6**:37289.
- 39 13. Tristan-Manzano M, Justicia-Lirio P, Maldonado-Perez N, et al. Externally-Controlled
40 Systems for Immunotherapy: From Bench to Bedside. *Front Immunol* 2020;**11**:2044.
- 41 14. Calvez R, Lafouresse F, De Meester J, et al. The Wiskott-Aldrich syndrome protein permits
42 assembly of a focused immunological synapse enabling sustained T-cell receptor
43 signaling. *Haematologica* 2011;**96**(10):1415-23.
- 44 15. Cotta-de-Almeida V, Dupre L, Guipouy D, et al. Signal Integration during T Lymphocyte
45 Activation and Function: Lessons from the Wiskott-Aldrich Syndrome. *Front Immunol*
46 2015;**6**:47.

- 1 16. Martin F, Toscano MG, Blundell M, et al. Lentiviral vectors transcriptionally targeted to
2 hematopoietic cells by WASP gene proximal promoter sequences. *Gene Ther*
3 2005;**12**(8):715-23.
- 4 17. Navarro-Marchal SG-L, Carmen; Entrena, Jose-Manuel; Ruiz-Alcala, Gloria; Tristán-
5 Manzano, Maria; Martín, Francisco; Pérez-Victoria, Ignacio; Peula-Garcia, José
6 Manuel; Marchal, Juan A. Anti-CD44-conjugated olive oil liquid nanocapsules for
7 targeting pancreatic cancer stem cells. *Biomacromolecules* 2021.
- 8 18. Demaison C, Parsley K, Brouns G, et al. High-level transduction and gene expression in
9 hematopoietic repopulating cells using a human immunodeficiency [correction of
10 imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen
11 focus forming virus promoter. *Hum Gene Ther* 2002;**13**(7):803-13.
- 12 19. Castella M, Caballero-Banos M, Ortiz-Maldonado V, et al. Point-Of-Care CAR T-Cell
13 Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From
14 an Academic Phase I Clinical Trial. *Front Immunol* 2020;**11**:482.
- 15 20. Mayer B, Stahl V, Kron M. The use of gatekeeping procedures in the statistical planning of
16 animal experiments. *Altern Lab Anim* 2017;**45**(6):317-28.
- 17 21. Castella M, Boronat A, Martín-Ibanez R, et al. Development of a Novel Anti-CD19
18 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at
19 Academic Institutions. *Mol Ther Methods Clin Dev* 2019;**12**:134-44.
- 20 22. Marofi F, Motavalli R, Safonov VA, et al. CAR T cells in solid tumors: challenges and
21 opportunities. *Stem Cell Res Ther* 2021;**12**(1):81.
- 22 23. Martinez M, Moon EK. CAR T Cells for Solid Tumors: New Strategies for Finding,
23 Infiltrating, and Surviving in the Tumor Microenvironment. *Front Immunol*
24 2019;**10**:128.
- 25 24. Rodriguez-Garcia A, Palazon A, Noguera-Ortega E, et al. CAR-T Cells Hit the Tumor
26 Microenvironment: Strategies to Overcome Tumor Escape. *Front Immunol*
27 2020;**11**:1109.
- 28 25. Wagner DL, Fritsche E, Pulsipher MA, et al. Immunogenicity of CAR T cells in cancer
29 therapy. *Nat Rev Clin Oncol* 2021.
- 30 26. Finney OC, Brakke HM, Rawlings-Rhea S, et al. CD19 CAR T cell product and disease
31 attributes predict leukemia remission durability. *J Clin Invest* 2019;**129**(5):2123-32.
- 32 27. Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion
33 induced by tonic signaling of chimeric antigen receptors. *Nat Med* 2015;**21**(6):581-90.
- 34 28. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine
35 Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
36 *Biol Blood Marrow Transplant* 2019;**25**(4):625-38.
- 37 29. Wei J, Liu Y, Wang C, et al. The model of cytokine release syndrome in CAR T-cell
38 treatment for B-cell non-Hodgkin lymphoma. *Signal Transduct Target Ther*
39 2020;**5**(1):134.
- 40 30. Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release
41 syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
42 *Blood* 2019;**133**(7):697-709.
- 43 31. Hao Z, Li R, Meng L, et al. Macrophage, the potential key mediator in CAR-T related CRS.
44 *Exp Hematol Oncol* 2020;**9**:15.

Physiological (TCR-like) regulated lentiviral vectors for the generation of improved CAR-T cells

Authors

María Tristán-Manzano, Noelia Maldonado-Pérez, Pedro Justicia-Lirio, Pilar Muñoz, Marina Cortijo, Kristina Pavlovic, Rosario Jiménez-Moreno, Sonia Nogueras, MDolores Carmona, Sabina Sánchez-Hernández, Araceli Aguilar-González, María Castella, Manel Juan, Concepción Marañón, Karim Benabdellah, Inmaculada Herrera and Francisco Martin.

Correspondence

f.martin@genyo.es

In Brief

Current CAR-T cells products use strong promoters to drive CAR expression which lead to high activation, tonic signalling and premature differentiation. Here, we propose the WAS promoter, which drives a partial decrease in CAR expression, as an alternative for the generation of TCR-like CAR-T cells in a LV context with improved characteristics.

FIGURES CAPTION

Figure 1. T cells transduced with WAS promoter-driven LVs mimic the TCR expression pattern. A) Top: Timeline of the experiments to study eGFP expression pattern after TCR/CAR stimulation. Bottom: diagrams of the different used eGFP-expressing LVs analyzed. B) Fold change of CD3 expression (% relative to 0h) in WT T cells stimulated with α CD3/ α CD28 and α CD19CAR-T cells stimulated with CD19+ cells. Left: fold change in CD3 expression at different times post-stimulation. (Data are MeFI $\pm$ SEM *, indicates p<0,05, 2-way-ANOVA, Bonferroni post-Test. n $\geq$ 5). Right: Representative histograms showing CD3 expression on WT T cells (left) and α CD19CAR-T cells (right) at different times post-stimulation. C) Representative histograms of eGFP expression driven by strong-promoter driven (CEWP, SE and EFEWP- top panels) and WAS-promoter driven (WE, AWE – bottom panels) LVs at different times post-stimulation. D, E) Graphs showing fold change in eGFP (colored lines) and CD3 (black lines) expression along time after α CD3/ α CD28 stimulation of T cells transduced with viral promoter-driven (CEWP, SEWP) (D) or eukaryotic-promoters driven (EFEWP, WE and AWE) LVs (E). Fold change is calculated by the following formula: ((MeFI of GFP+ population xh/ MeFI of non-transduced cells xh)/ MeFI of GFP+ population 0h/ MeFI of non-transduced cells 0h). 2-way-ANOVA, Bonferroni post-Test, compared with CD3 pattern: *, p<0.05; **, p<0.01; ***, p<0.001. +++ indicates p<0.001 for SEWP compared to CD3 expression. n=5. F) Diagrams of the EF1a promoter-driven (ARI) and WAS-promoter driven (AWARI) LVs expressing the ARI-0001 CAR (α CD19 A3B1-41BB-CD3 ζ) G) Representative histograms of CAR expression levels on CAR-T cells generated with the ARI (top) or AWARI (bottom) LVs and measured at different time points after activation with CD19+ cells (left) or α CD3/ α CD28 (right). H, I) Graphs showing fold change in CAR expression on ARI-CAR-T (green lines) and AWARI-CAR-T (blue lines) cells at different time points after activation with CD19+ cells (H) or α CD3/ α CD28 (I). Data shows the percentage of CAR+ cells at different time points relative to 0 hours. Man-Whitney test, two tails, ** indicates p<0.01 compared to CD3 and + indicates p<0,05 compared to AWARI-CAR-T cells. n $\geq$ 5.

1 **Figure 2. TCR-like expression improves CAR-T cells properties *in vitro*.** A) Top:
2 Representative histograms of LAG-3, PD1 and Tim3 expression of NTD (non-transduced,
3 gray), ARI (blue) and AWARI (green) CAR-T cells determined 10 days after activation with
4 α CD3/CD28. Bottom: Graphs showing expression levels of LAG-3, PD1 and Tim3 of ARI
5 and AWARI CAR-T cells related to the expression in NTD cells. Data are MeFI $\pm$ SEM.
6 One-tailed Man-Whitney test (4 independent-donors). B) Left: Representative histograms of
7 intracellular phospho-CD3z expression after 10 days post-initial activation of NTD (gray),
8 ARI (blue) and AWARI (green) CAR-T cells. Right: Graph showing pCD3z expression
9 levels of each CAR-T cells related to NTD cells. Represented data is the ratio of pCD3z
10 MeFI of ARI or AWARI CAR-T cells divided by the pCD3z MeFI of NTD cells. One-tailed
11 Man-Whitney test (4 independent-donors, $n \geq 4$). C) Lysis of CD19+ cells (Nalm6 and
12 Namalwa) at different ratios of co-culture with ARI and AWARI-CAR-T cells during 48h.
13 Percentage of lysis is related to NTD-driven non-specific CD19+ lysis ($n=5$). D) Relative
14 expression levels of LAG-3 on ARI and AWARI CAR-T cells 48h after co-culture with
15 Nalm6 (left) or Namalwa (right) cells. Data represents LAG-3MeFI of ARI or AWARI
16 CAR-T cells divided by the LAG-3 MeFI of NTD cells. One-tailed Man-Whitney test ($n \geq 5$).
17 E) Levels of secreted TNF α (left) and IFN γ (right) produced by NTD, ARI and AWARI
18 CAR-T cells after 24h of stimulation with Namalwa at ratio 1:1 and determined by ELISA (4
19 independent-donors, $n \geq 4$).

20

21 **Figure 3. *In vivo* anti-tumor activity and phenotype of ARI and AWARI CAR-T cells.**

22 A) Experimental design of *in vivo* antitumor activity and phenotypic studies of 5e6 (purple
23 dots) and a 10e6 (blue dots) of ARI and AWARI CAR-T cells. Re-challenge with new
24 Namalwa is indicated with an arrow at day 16 in the 10e6 dose. Phenotypic analysis was
25 performed after sacrifice at day 13 for 5e6 dose and day 28 for 10e6 dose. B) Tumor
26 bioluminescence (BLI) progression with 5e6 (left) and 10e6 T cells doses (right) at different
27 days post-Namalwa inoculation. C) Percentage of surviving Namalwa-GFP-Nluc cells in

1 bone marrow (BM), spleen, blood, liver and blood determined by FACS after the sacrifice
2 with the low (left panels) and high (right panels) doses. This value is analyzed in “singlets
3 human cells” gate (see M&M). Two-tailed Mann-Whitney test, *, $p<0.05$; **, $p<0.01$, and
4 ***, $p<0.001$. N(mice) of low dose: PBS=3, NTD=3, ARI=3, AWARI=3; and high dose:
5 PBS=2, NTD=3, ARI=8, AWARI=5. D) Representative dot-plots of CAR expression and
6 phenotype of CAR⁺ cells of gated hCD3 from the spleen of ARI and AWARI mice after
7 sacrifice of the high-dose experiment. E) Graphical representation of proportions of T_N/T_{SCM}
8 (CD62L+CD45RA⁺) (green), T_{CM} (CD62L+CD45RA⁻) (blue), T_{EM} (CD62L-CD45RA⁻)
9 (grey) and T_{EF} (CD62L-CD45RA⁺) (red) subpopulations in ARI (top) and AWARI (bottom)
10 CAR⁺ cells in the indicated organs after sacrifice of challenged (outer circle) and re-
11 challenged (inner circle) mice. *, $p<0.05$ when compared the T cells subsets of re-challenged
12 ARI and AWARI treated mice. Mann-Whitney one-tail. ++ and +++ $p<0.01$ and $p<0.001$
13 respectively of 2-way ANOVA, Bonferroni post-Test of all the population of the total mice
14 (ARI=8 (3+5R), AWARI=5 (2+3R)). F) Percentage of T_N/T_{SCM} and T_{CM} after sacrifice of ARI
15 and AWARI hCD3+CAR⁺ cells (ARI=8, AWARI=5, Mann-Whitney one-tail. G) Spleen
16 from treated mice were isolated and cells suspensions were cultured with 200 UI/ml of IL-2
17 in TexMACS medium and 2% P/S during 48h. H) Representative dot-plots of
18 CD45RA/CD62L and PD1/LAG3 populations of ARI and AWARI mice. I) Percentage of
19 hCD3+ T_N/T_{SCM} and T_{CM} after 48h of *in-vitro* culture. Two-tailed Mann-Whitney test (N=4).
20 J) Percentage of PD1+LAG3⁺ cells. One-tailed Mann-Whitney test (N=4).

21

22 **Figure 4. GMP-like large-scale production of AWARI CAR T cells.** A) Time-line of the
23 GMP-like batches #01 and #02 of AWARI CAR-T cells in the CliniMACS Prodigy. B) Dot-
24 plots of CAR expression at days of sample (7/6) and final product (10/9) for both #01 (left) and
25 #02 (right) batches. C) Data from viability, number of CD3, efficiency of CAR-T cell
26 transduction and number of obtained CAR-T cells. FC= flow cytometry, NC= Neubauer
27 chamber counting. D) Variation of percentage of CD4 and CD8⁺ cells in CAR⁻ and CAR⁺ cells

1 at sample (s) and final products (f). Two-tailed Mann-Whitney test. E) Graphical representation
2 of the T cells populations at sample (days 6 or 7) and final products (day 9 or 10).
3 T_N/T_{SCM} =Naïve/stem cell memory (CD45RA+CCR7+), T_{CM} = central memory (CD45RA-
4 CCR7+), T_{EM} = effector memory (CD45RA-CCR7-) and T_{EMRA} = effector memory
5 RA+(CD45RA+CCR7-). F) *In vitro* specific lysis of CD19+ cells Nalm6 (left) and Namalwa
6 (right) CD19+ cells by AWARI CAR-T cells harvested at sample day (black line) and final day
7 (red line) for productions #01 and #02. CAR-T cells products were co-cultured at different
8 ratios during 16h (dashed line) or 48h (continuous line).

9

10

11 **Figure 5. *In vivo* anti-tumor activity and phenotype of CliniMACS-produced AWARI-**
12 **CAR-T cells after one or two Namalwa challenges.** A) Experimental design and time-line of
13 the two experiments with CliniMACS batches #01 and #02. R indicates re-challenge. B)
14 Survival of PBS, NTD or AWARI-inoculated mice of #01 and #02 products. Log-Ranked test.
15 C, D) Representative BLI images of tumor burden measured in #01 (C) and #02 (D)
16 experiments at different days post Namalwa inoculation as indicated. In both studies, at day 15
17 (#01) or 13 (#02) respectively, new Namalwa cells were inoculated to AWARI treated mice (re-
18 challenge, yellow line) and to control mice ('New PBS'). E) Representative dot-plots of
19 Namalwa/hCD3 presence, CAR+ cells of hCD3 and phenotype of CAR- and CAR+ of NTD
20 cells and AWARI CliniMACS #01 from BM after sacrifice. F) Percentage of $T_N/T_{SCM}+T_{CM}$
21 population in hCD3+CAR+ cells analyzed in different organs from mice with one or two
22 (rechallenge, R) inoculations of Namalwa tumor cells in #01 (left) and #02 (right) CliniMACS
23 batches at final day. Only when CAR+ population was >1%, data was analyzed and included
24 here. N (CliniMACS #01): PBS=3, NTD=5, AWARI=10 (2 sacrificed at day 13, 4 mice with
25 one- and 4 mice with two-challenges. N (CliniMACS #02): PBS=2, NTD=3, AWARI =5 (2+3
26 re-challenged mice). 2-way-ANOVA, Bonferroni Post Test, *, indicates $p<0.05$, **, $p<0.001$,
27 ***, $p<0.0001$.

1

2